Date: 2013-09-09
Type of information: Fundraising
Company: DuecomplusA (UK), subsidiary of drug delivery specialists Moreinx (Sweden)
Investors:
Amount: € 1 million
Funding type: crowdfunding
Planned used: These funds will be used to support Phase I/II trials of DUE-C100.
Others: * On September 10, 2013, DuecomplusA, a subsidiary of drug delivery specialists Moreinx AB, has announced it was turning to crowdsourcing to fund Phase I/II trials of DUE-C100, its new QS (Quillaja saponaria Molina) nanoparticle based treatment for Acute Myleoid Leukemia (AML). This compound is based on ground breaking science by Professor Bror Morein and his team. DUE-C100 is based on saponin fractions of Quillaja saponaria Molina (QS) which have long been known to have cytotoxic activity against cancer cells in vitro, but were considered too toxic to be useful in the clinic. Morein and his team have been able to abolish the toxic effect by converting QS fractions into stable nanoparticles through the binding of QS to cholesterol. Two fractions of QS were selected for particle formation, one with anacyl-chain (ASAP) was used to form killing and growth-inhibiting (KGI) particles, and the other without the acyl-chain (DSAP) was used to formulate blocking and balancing effect (BBE) particles. KGI showed significant growth inhibiting and cancer cell-killing activities in nine of 10 AML cell lines while BBE showed similar effects on one cell line. If the funding is successful, the company would look to start testing this theory in the clinic by early 2014.
Therapeutic area: Cancer - Oncology
